Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
No Thumbnail Available
Identifiers
Date
2018-10-01
Authors
Morgensztern, D.
Govindan, R.
Cobo, M.
Ponce Aix, S.
Postmus, P. E.
Lewanski, C.
Bennouna, J.
Fischer, J.
Juan-Vidal, O.
Stewart, D.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
nab-paclitaxel, survival, durvalumab